Comparative associations of Anakinra and Tocilizumab initiation with in-hospital mortality in severe COVID-19: A single-center sequential cohort study.

Publication date: Sep 03, 2026

Interleukin-1 and interleukin-6 blockade have been widely used in severe COVID-19, but comparative real-world evidence regarding anakinra and tocilizumab in critically ill patients remains limited. We evaluated the associations of first initiation of anakinra or tocilizumab with 28-day and overall in-hospital mortality. This single-center retrospective ICU cohort included adults with severe COVID-19. During hospital days 2-10, daily actions were classified as anakinra initiation, tocilizumab initiation, or control/defer. Calibrated overlap-weighted modified-Poisson models estimated associations with 28-day and overall in-hospital mortality; ferritin-adjusted sensitivity analyses were performed. Of 306 patients, 241 patients contributed 1,297 eligible person-days. Calibration met the prespecified balance criterion for the included covariates, although effective support for tocilizumab initiation remained limited. For 28-day in-hospital mortality, adjusted RRs versus control/defer were 0. 99 (95% CI, 0. 80-1. 22) for anakinra and 0. 99 (95% CI, 0. 71-1. 37) for tocilizumab. No clear associations were identified in the head-to-head comparison or for overall in-hospital mortality; ferritin-adjusted estimates were similar. In this retrospective ICU cohort, neither anakinra nor tocilizumab initiation showed a clear association with 28-day or overall in-hospital mortality. Estimates were imprecise, particularly for tocilizumab, and remain susceptible to residual confounding.

Open Access PDF

Concepts Keywords
Aged
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Humanized
Betacoronavirus
Coronavirus Infections
COVID-19
COVID-19 Drug Treatment
Female
Hospital Mortality
Humans
Intensive Care Units
Male
Middle Aged
Pneumonia, Viral
Retrospective Studies
SARS-CoV-2
tocilizumab

Semantics

Type Source Name
drug DRUGBANK Anakinra
drug DRUGBANK Tocilizumab
disease MESH COVID-19
disease MESH critically ill
disease MESH included
drug DRUGBANK Methionine
drug DRUGBANK Isoxaflutole
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH asymptomatic infection
disease MESH pneumonia
disease MESH death
disease MESH cytopenia
disease MESH hyperferritinemia
disease MESH cytokine storm syndrome
drug DRUGBANK L-Phenylalanine
disease MESH infection
disease MESH acute respiratory distress syndrome
disease MESH syndrome
disease MESH emergency
disease MESH clinical deterioration
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Medical air
drug DRUGBANK Oxygen
drug DRUGBANK Acetylsalicylic acid
drug DRUGBANK Favipiravir
drug DRUGBANK Enoxaparin
drug DRUGBANK Dexamethasone
disease MESH respiratory failure
disease MESH SMD
disease MESH kidney disease
drug DRUGBANK Creatinine
disease MESH chronic kidney disease
disease MESH End stage kidney disease
disease MESH Hypertension
disease MESH Diabetes mellitus
disease MESH Coronary artery disease
disease MESH Asthma
pathway KEGG Asthma
disease MESH Rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH Anxiety
drug DRUGBANK Urea
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Potassium
drug DRUGBANK Fibrinogen Human
disease MESH Coronavirus Infections
disease MESH Pneumonia Viral

Original Article

(Visited 5 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *